Metformin Regulates Gut Microbiota Abundance to Suppress M2 Skewing of Macrophages and Colorectal Tumorigenesis in Mice

Fan, Linfeng; Zeng, Xiangfu; Xu, Guofeng

doi:10.1007/s12275-022-00010-8

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have indicated that certain bacteria may promote the occurrence and development of CRC. Metformin is thought to exert its preventive and therapeutic effects on CRC by affecting the intestinal flora [ 29 – 31 ]. As research progresses, the significance of changes in the intestinal flora of FAP patients is becoming increasingly acknowledged.…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Zhou,

Zheng,

et al. 2024

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background and aims Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora. Studies have also indicated that the occurence of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora. Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora. Results Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. These changes were statistically significant (P < 0.05). Conclusion One-year metformin therapy for FAP is safe and effective, potentially mediated by modulating the intestinal flora. This study provides new insights and strategies for preventing adenomatous polyp carcinogenesis in FAP and explores possible preventive action.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Zhou,

Zheng,

et al. 2024

Orphanet J Rare Dis

View full text Add to dashboard Cite

show abstract

“…However, the side-effects of these drugs also limit their longterm use. Metformin is a classic rst-line antidiabetic drug, which is well-known for its antitumor effects [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Zhou,

Zheng,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and aims :Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora.Studies have also indicated that the occurance of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora.Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora. Results Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. All these changes were statistically significant (p < 0.05). Conclusion One-year metformin therapy for FAP is safe and effective, and maybe mediated by modulating the intestinal flora. This study provides new ideas and strategies for the prevention of adenomatous polyp carcinogenesis in FAP and possible mechanisms of preventive action.

show abstract

Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFκB/MAPK pathway and macrophage M2 polarization

Lai,

Liu,

Wan

et al. 2025

International Immunopharmacology

View full text Add to dashboard Cite

Metformin Regulates Gut Microbiota Abundance to Suppress M2 Skewing of Macrophages and Colorectal Tumorigenesis in Mice

Cited by 4 publications

References 39 publications

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFκB/MAPK pathway and macrophage M2 polarization

Contact Info

Product

Resources

About